RxDoctor Payments Data

Erin Flaherty

Physician Assistant · Gibsonia, PANPI 1609421932

Payments from drug & device makers

$1,066in general payments, 2019–2025

Across 22 payments — averaging $48.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$236
  • Daiichi Sankyo Inc.$125
  • AstraZeneca$125
  • Epizyme, Inc.$122
  • Amgen$91
  • Acrotech Biopharma Inc.$90
  • plus $277 from 11 others

What the payments were for

  • Speaking & faculty fees$908%
  • Food & beverage$97692%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,066 in reported general payments places this provider in the 75th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$1,669
Medicare patients
17
Services billed
18

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban109$84,161
XareltoRivaroxaban40$24,475
Anastrozole60$1,026
Letrozole17$315
Oxycodone Hcl23$240
Acyclovir14$211
Dexamethasone16$208
Potassium Chloride16$171
Warfarin Sodium22$158
Allopurinol12$115
Prednisone17$79
Levothyroxine Sodium12$50
Pantoprazole Sodium13$38

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$67$24,47540 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Gibsonia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →